

BREAKTHROUGH THERAPIES: MARKET DYNAMICS AND INVESTMENT OPPORTUNITIES



PHM176A
January 2017

Dr. Cheryl Lee Barton
Project Analyst

ISBN: 1-62296-431-4



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
info@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE REPORT	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
METHODOLOGY AND INFORMATION SOURCES	3
ANALYSTS' CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	3
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL MARKET FOR BREAKTHROUGH THERAPY DESIGNATION DRUGS, BY THERAPY, THROUGH 2022 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR BREAKTHROUGH THERAPY DESIGNATION DRUGS, BY THERAPY, 2015-2022 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW	9
DEFINING BREAKTHROUGH THERAPY DESIGNATION	9
QUALIFYING CRITERIA FOR BREAKTHROUGH THERAPY DESIGNATION	9
Serious Condition	9
Existing (or Available) Therapies	10
Preliminary Clinical Evidence	10
May Demonstrate Substantial Improvement on Clinically Significant Endpoint(s)	10
THE BENEFITS OF BREAKTHROUGH THERAPY DESIGNATION	12
FDA'S APPROACHES TO EXPEDITED DRUG DEVELOPMENT	12
DRUGS GRANTED BREAKTHROUGH THERAPY DESIGNATION	13
<i>TABLE 1 CDER BREAKTHROUGH THERAPY DESIGNATION REQUESTS RECEIVED BY FISCAL YEAR COHORT: JULY 9, 2012*-SEPTEMBER 30, 2015</i>	14
<i>TABLE 2 CBER BREAKTHROUGH THERAPY REQUESTS FOR FINAL YEAR, OCTOBER 1, 2014-SEPTEMBER 30, 2015</i>	14
<i>FIGURE 1 BREAKTHROUGH THERAPY REQUESTS GRANTED BY DIVISION, 2015* (%)</i>	15
PRIME (PRIORITY MEDICINE) SCHEME	16
<i>FIGURE 2 PRIME SCHEME APPLICATIONS AND ELIGIBILITY</i>	16
<i>FIGURE 3 PRIME DRUG BY TYPE OF APPLICATION AND THERAPEUTIC AREA</i>	17
<i>FIGURE 4 PRIME DRUG APPLICATIONS, THERAPEUTIC AREA</i>	18
<i>TABLE 3 DRUGS GRANTED PRIME DESIGNATIONS, MARCH 7, 2016-AUGUST 24, 2016</i>	18
CHAPTER 4 COMMERCIAL APPLICATION OF BREAKTHROUGH THERAPY DESIGNATION	22
INTRODUCTION	22
<i>FIGURE 5 FDA APPROVALS, BREAKTHROUGH THERAPY DESIGNATION AND DESIGNATION RESCINDED, BY STATUS, 2012-2016 (NUMBER)</i>	22
<i>FIGURE 6 FDA APPROVALS, BREAKTHROUGH DESIGNATION AND DESIGNATION RESCINDED, BY THERAPY AREA, 2012-2016 (NUMBER)</i>	23
CARDIOVASCULAR	24

TOPIC	PAGE NO.
<i>FIGURE 7 CARDIOVASCULAR BREAKTHROUGH THERAPY DESIGNATION DRUGS, BY STAGE (NUMBER)</i>	24
<i>TABLE 4 GLOBAL MARKET FOR CV BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)</i>	25
CV - BTD DRUGS APPROVED	25
<i>TABLE 5 FDA APPROVED CV BREAKTHROUGH THERAPY DESIGNATION DRUGS</i>	25
Promacta/Revolade (Eltrombopag Olamine: Novartis/GlaxoSmithKline)	26
BTD: February 6, 2014	26
Drug Class: Thrombopoietin Receptor Agonist (Small Molecule)	26
Indication: Severe Aplastic Anemia (SAA; CV)	26
Clinical Stage: Approved	26
Forecast	26
<i>TABLE 6 GLOBAL MARKET FOR PROMACTA, THROUGH 2022 (\$ MILLIONS/%)</i>	27
Praxbind (Idarucizumab; Boehringer Ingelheim)	27
BTD: June 30, 2014	27
Drug Class: Humanized Antibody Fragment (Biologic)	27
Indication: Reversal of Bleeding and Clotting Associated with Pradaxa (CV)	27
Clinical Stage: Approved	27
Forecast	28
<i>TABLE 7 GLOBAL MARKET FOR PRAXBIND, THROUGH 2022 (\$ MILLIONS/%)</i>	28
CV - BTD IN DEVELOPMENT	28
<i>TABLE 8 UNDER DEVELOPMENT CV BREAKTHROUGH THERAPY DESIGNATION DRUGS</i>	28
Reasanz (Serelaxin; Novartis)	29
BTD: June 21, 2013	29
Drug Class: Human Relaxin 2 Hormone (Biologic)	29
Indication: Acute Heart Failure (AHF; CV)	29
Clinical Stage	29
Forecast	30
<i>TABLE 9 GLOBAL MARKET FOR REASANZ, THROUGH 2022 (\$ MILLIONS/%)</i>	30
Actemra/RoActemra (Tocilizumab; Roche)	31
BTD: June 10, 2015, and August 5, 2016	31
Drug Class: Humanized Anti Interleukin L-6 Receptor mAb (Biologic)	31
Indication: Systemic Sclerosis and Giant Cell Arteritis (CNS/Rare Disease)	31
Clinical Stage: Approved/Phase 3 BTD	32
SSC Trial	32
CGA Trials	32
Forecast	32
<i>TABLE 10 GLOBAL MARKET FOR ACTEMRA/ROACTEMRA, THROUGH 2022 (\$ MILLIONS/%)</i>	32
CENTRAL NERVOUS SYSTEM AND NEUROLOGICAL DISORDERS	33
<i>FIGURE 8 CNS BREAKTHROUGH THERAPY DESIGNATION DRUGS, BY STAGE, 2016 (NUMBER)</i>	33
<i>TABLE 11 GLOBAL MARKET FOR CNS BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)</i>	34
CNS - BTD DRUGS APPROVED	34

TOPIC	PAGE NO.
TABLE 12 FDA APPROVED CNS BREAKTHROUGH THERAPY DESIGNATION DRUGS	34
Nuplazid (Primavanserin; Acadia Pharmaceuticals)	34
BTD: February 9, 2014	34
Drug Class: Selective Serotonin Inverse Agonist (Small Molecule)	35
Indication: Major Depressive Disorder	35
Clinical Stage: Approved	35
Forecast	35
TABLE 13 GLOBAL MARKET FOR NUPLAZID, THROUGH 2022 (\$ MILLIONS/%)	35
CNS - BTD IN DEVELOPMENT	36
TABLE 14 UNDER DEVELOPMENT CNS BREAKTHROUGH THERAPY DESIGNATION DRUGS	36
Deutetrabenazine ER (Teva Pharmaceuticals)	37
BTD: November 9, 2015	37
Drug Class: Vesicular Monoamine 2 Transporter Inhibitor (Small Molecule)	37
Indication: Tardive Dyskinesia (CNS)	37
Clinical Stage: Phase 2/3	38
Forecast	38
TABLE 15 GLOBAL MARKET FOR DEUTETRABENAZINE ER, THROUGH 2022 (\$ MILLIONS/%)	38
Ingrezza (Valbenazine; Neuroscience Biosciences)	38
BTD: October 30, 2014	38
Drug Class: Vesicular Monoamine 2 Transporter Inhibitor (Small Molecule)	39
Indication: Tardive Dyskinesia (CNS)	39
Clinical Stage: Phase 3	39
Kinect 2 - Phase 2b	39
Kinect 3 - Phase 3	39
Forecast	39
TABLE 16 GLOBAL MARKET FOR INGREZZA, THROUGH 2022 (\$ MILLIONS/%)	40
Arzerra (Ofatumumab; Novartis/Genmab)	40
BTD: October 11, 2013	40
Drug Class: Human Monoclonal Antibody Targeting CD20-Positive B Cells (Biologic)	40
Indication: Relapse Remitting Multiple Sclerosis (CNS/Autoimmune)	40
Clinical Stage: Phase 3	40
Forecast	41
TABLE 17 GLOBAL MARKET FOR OF OFATUMUMAB, THROUGH 2022 (\$ MILLIONS/%)	41
Oliceridine (TRV130; Trevena)	42
BTD: February 22, 2016	42
Drug Class: M Opioid Receptor Agonist (Small Molecule)	42
Indication	42
Clinical Stage: Phase 3	42
Forecast	43
TABLE 18 GLOBAL MARKET FOR OLICERIDINE, THROUGH 2022 (\$ MILLIONS/%)	43
Rapastinel (GLYX-13; Allergan)	43
BTD: January 31, 2016	43
Drug Class: NMDA Partial Receptor Antagonist (Small Molecule)	43

TOPIC	PAGE NO.
Indication: Major Depressive Disorder (CNS)	43
Clinical Stage: Phase 2	44
Forecast	44
<i>TABLE 19 GLOBAL MARKET FOR RAPASTINEL, THROUGH 2022 (\$ MILLIONS/%)</i>	45
Sepranolone (UC1010; Asarina Pharma)	45
TD: February 22, 2016	45
Drug Class: GABA-A Modulating Steroid Antagonist (Small Molecule)	45
Indication: Premenstrual Dysphoric Disorder (PMDD)	45
Clinical Stage: Phase 2	45
Forecast	46
<i>TABLE 20 GLOBAL MARKET FOR SEPRANOLONE, THROUGH 2022 (\$ MILLIONS/%)</i>	46
NaBen (SND-13; SyneuRx International Corporation)	46
BTD: December 10, 2014	46
Drug class: D-Amino Acid Oxidase (DAAO) Inhibitor (Small Molecule)	46
Indication: Schizophrenia (CNS)	47
Clinical Stage: Phase 2/3	47
Forecast	47
<i>TABLE 21 GLOBAL MARKET FOR SND-13, THROUGH 2022 (\$ MILLIONS/%)</i>	47
AVXS-101 (AveXis)	47
BTD: July 20, 2016	47
Drug Class: Gene Therapy (Biologic)	48
Indication: Spinal Muscular Atrophy (SMA; Rare Disease)	48
Clinical Stage: Phase 1	48
Forecast	48
<i>TABLE 22 GLOBAL MARKET FOR AVXS-101, THROUGH 2022 (\$ MILLIONS/%)</i>	49
Esketamine (Johnson & Johnson)	49
BTD: November 2013 and August 16, 2016	49
Drug Class: N-methyl-D-aspartate (NMDA) Receptor Antagonist (Small Molecule)	49
Indication: Major Depressive Disorder (MDD)	49
Clinical Stage: Phase 3	49
Forecast	50
<i>TABLE 23 GLOBAL MARKET FOR ESKETAMINE, THROUGH 2022 (\$ MILLIONS/%)</i>	50
RBP-8000 (Indivior)	50
BTD: November 18, 2014	50
Drug Class: Cocaine Esterase Rescue Blocker (Small Molecule)	50
Indication: Cocaine Abuse	50
Clinical Stage: Phase 2	51
Forecast	51
<i>TABLE 24 GLOBAL MARKET FOR RBP-8000, THROUGH 2022 (\$ MILLIONS/%)</i>	51
INFECTIOUS DISEASES	51
<i>FIGURE 9 INFECTIOUS DISEASE BREAKTHROUGH THERAPY DESIGNATION DRUGS, BY STAGE, 2016 (NUMBER)</i>	52
<i>TABLE 25 GLOBAL MARKET FOR INFECTIOUS DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)</i>	53
INFECTIOUS DISEASES - BTD APPROVED	53

TOPIC	PAGE NO.
<i>TABLE 26 FDA APPROVED INFECTIOUS DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS, 2016</i>	53
Sovaldi (Gilead Sciences)	54
BTD: December 6, 2013	54
Drug Class: Nucleotide Analog Inhibitor (Small Molecule)	54
Indication: Hepatitis C Virus (Infectious Diseases)	54
Clinical Stage: Approved	54
Forecast	54
<i>TABLE 27 GLOBAL MARKET FOR SOLVADI, THROUGH 2022 (\$ MILLIONS/%)</i>	55
Epclusa (Gilead Sciences)	55
BTD: April 22, 2014	55
Drug Class: Nucleotide Analog Inhibitor + Pan-Genotypic NS5A Inhibitor (Small Molecule)	55
Indication: Hepatitis C Virus (Infectious Disease)	55
Clinical Stage: Approved	56
Forecast	56
<i>TABLE 28 GLOBAL MARKET FOR EPCLUSA, THROUGH 2022 (\$ MILLIONS/%)</i>	56
Technivie/Viekirax (AbbVie)	57
BTD: June 30, 2014	57
Drug Class: Fixed Dose Triple Antiviral (Small Molecule)	57
Indication: Hepatitis C Virus (Infectious Disease)	57
Clinical Stage: Phase 3	57
Forecast	57
<i>TABLE 29 GLOBAL MARKET FOR VIEKERA/TECHNIVIE, THROUGH 2022 (\$ MILLIONS/%)</i>	58
Zepatier (Elbasvir/Grazoprevir; Merck)	58
BTD: October 1, 2013	58
Drug Class: NS5A Inhibitor, NS3/4A Protease Inhibitor (Small Molecule)	58
Indication: Hepatitis C Virus (Infectious Disease)	58
Clinical Stage: Approved	59
Forecast	59
<i>TABLE 30 GLOBAL MARKET FOR ZEPATIER, THROUGH 2022 (\$ MILLIONS/%)</i>	59
Harvoni (Gilead Sciences)	60
BTD: October 10, 2014	60
Drug Class: NS5A Inhibitor NS5B Inhibitor (Small Molecule)	60
Indication: Hepatitis C Virus (Infectious Disease)	60
Clinical Stage: Approved	60
Forecast	60
<i>TABLE 31 GLOBAL MARKET FOR HARVONI, THROUGH 2022 (\$ MILLIONS/%)</i>	61
INFECTIOUS DISEASES - BTD IN DEVELOPMENT	61
<i>TABLE 32 UNDER DEVELOPMENT INFECTIOUS DISEASE BREAKTHROUGH THERAPY DESIGNATION DRUGS, 2016</i>	61
Arikayce (Amikacin Sulfate; Insmed)	62
BTD: June 20, 2014	62
Drug Class: Aminoglycoside Antibiotic. (Small Molecule)	62
Indication: Nontuberculous Mycobacterial (NTM; Infectious Disease)	62
Clinical Stage: Phase 3	62

TOPIC	PAGE NO.
Forecast	63
<i>TABLE 33 GLOBAL MARKET FOR ARIKAYCE, THROUGH 2022 (\$ MILLIONS/%)</i>	63
Fostemsavir (ViiV Healthcare)	63
BTD: July 22, 2015	63
Drug Class: Fusion Inhibitor (Small Molecule)	63
Indication: Human Immunodeficiency Virus (HIV)	63
Clinical Stage: Phase 3	64
Forecast	64
<i>TABLE 34 GLOBAL MARKET FOR FOSTEMSAVIR, THROUGH 2022 (\$ MILLIONS/%)</i>	64
Glecaprevir/Pibrentasvir (ABT-493/ABT-530; AbbVie/Enanta Pharmaceuticals)	64
BTD: September 30, 2016	64
Drug Class: NS3 Protein Inhibitor (Small Molecule)	64
Indication: Hepatitis C Virus (HCV; Infectious Disease)	65
Clinical Stage: Phase 2	65
Forecast	65
<i>TABLE 35 GLOBAL MARKET FOR GLECAPREVIR/PIBRENTASVIR, THROUGH 2022 (\$ MILLIONS/%)</i>	65
Ibalizumab (TaiMed Biologics/Theratechnologies)	66
BTD: February 2015	66
Drug Class: CD4 mAb (Biologic)	66
Indication: Human Immunodeficiency Virus (HIV)	66
Clinical Stage: Phase 3	66
Forecast	66
<i>TABLE 36 GLOBAL MARKET FOR IBALIZUMAB, THROUGH 2022 (\$ MILLIONS/%)</i>	67
Tafenoquine (GlaxoSmithKline/MMV)	67
BTD: 20 December, 2013	67
Drug Class: 8-Aminoquinoline Derivative (Small Molecule)	67
Indication: Hepatitis C Virus (HCV; Infectious Disease)	67
Clinical Stage: Phase 2	67
Forecast	68
<i>TABLE 37 GLOBAL MARKET FOR TAFENOQUINE, THROUGH 2022 (\$ MILLIONS/%)</i>	68
V920 (Merck & Co./NewLink Genetics Corporation)	68
BTD: 25, July 2016	68
Drug Class: Ebola Vaccine (Biologic)	68
Indication: Ebola Zane (Infectious Disease)	68
Clinical Stage: Phase 3	69
Forecast	69
<i>TABLE 38 GLOBAL MARKET FOR V920, THROUGH 2022 (\$ MILLIONS/%)</i>	69
ONCOLOGY	69
<i>FIGURE 10 CANCER DRUGS WITH BREAKTHROUGH THERAPY DESIGNATION, BY CANCER TYPE, 2016 (NUMBER OF APPROVED BTD DRUGS)</i>	69
<i>FIGURE 11 CANCER BREAKTHROUGH THERAPY DESIGNATION, BY COMPANY, 2016 (NO. OF BTD IN ONCOLOGY)</i>	71
<i>TABLE 39 GLOBAL MARKET FOR ONCOLOGY BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)</i>	72
ONCOLOGY - BTD DRUGS APPROVED	72
<i>TABLE 40 FDA APPROVED ONCOLOGY BREAKTHROUGH THERAPY DESIGNATION DRUGS, 2013-2015</i>	72

TOPIC	PAGE NO.
Alecensa (Alectinib; Genentech/Roche)	74
BTD: June 2013 and October 2016	74
Drug Class: Oral Inhibitor of Anaplastic Lymphoma Kinase (ALK) Inhibitor (Small Molecule)	74
Indication: ALK+ NSCLC (Oncology)	74
Clinical Stage: Approved	74
Second Line Therapy - NP28761 (Study 1)	74
Second Line Therapy - NP28673 (Study 2)	74
First Line Therapy - J-ALEX Study	75
Forecast	75
<i>TABLE 41 GLOBAL MARKET FOR ALENCENSA, THROUGH 2022 (\$ MILLIONS/%)</i>	76
Arzerra (Ofatumumab; GlaxoSmithKline/Genmab)	76
BTD: September 13, 2013	76
Drug Class: mAb Target CD20 (Biologic)	76
Indication: CLL	77
Clinical Stage: Approved	77
Forecast	77
<i>TABLE 42 GLOBAL MARKET FOR ARZERRA, THROUGH 2022 (\$ MILLIONS/%)</i>	78
Blincyto (Blinatumomab; Amgen)	78
BTD: December 3, 2014	78
Drug Class: CD3/CD19 BiTE Antibody (Biologic)	78
Indication: B-Cell ALL (Oncology)	78
<i>FIGURE 12 TREATMENT ALGORITHM FOR ALL PATIENTS</i>	79
Clinical Stage: Approved	79
Forecast	79
<i>TABLE 43 GLOBAL MARKET FOR BLINCYTO, THROUGH 2022 (\$ MILLIONS/%)</i>	80
Darzalex (Daratumumab; Genmab/Johnson & Johnson)	80
BTD: May 1, 2013, May 27, 2013, and July 2016	80
Drug Class: mAb CD38 (Biologic)	80
Indication: Multiple Myeloma (Oncology)	81
Clinical Stage: Phase 3	81
CASTOR Trial-Second Line	81
POLLUX Trial - Second Line	81
Forecast	82
<i>TABLE 44 GLOBAL MARKET FOR DARZALEX, THROUGH 2022 (\$ MILLIONS/%)</i>	82
Gazyva/Gazyvaro (Obinutuzumab; Genentech/Roche)	82
BTD: May 2013	82
Drug Class: mAb Targeting CD20 (Biologic)	82
Indication: CLL	82
Clinical Stage: Approved	83
Forecast	83
<i>TABLE 45 GLOBAL MARKET FOR GAZYVA, THROUGH 2022 (\$ MILLIONS/%)</i>	83
Ibrance (Palbociclib; Pfizer)	84
BTD: February 3, 2015	84
Indication: Her2 Metastatic Breast Cancer (Oncology)	84
Drug Class: CDK4/6 Inhibitor (Small Molecule)	84
Clinical Stage: Phase 3	84
PALOMA-2 Trial - Combination Therapy First-Line	84

TOPIC	PAGE NO.
PALOMA-3 - Combination Therapy	85
Forecast	85
<i>TABLE 46 GLOBAL MARKET FOR IBRANCE, THROUGH 2022 (\$ MILLIONS/%)</i>	86
Imbruvica (Ibrutinib; Johnson & Johnson/ Pharmacyclic)	86
BTD: January 2013	86
Drug Class: BTK Inhibitor (Small Molecule)	86
Indication: CLL (Oncology)	87
Clinical Phase: Approved	87
Forecast	87
<i>TABLE 47 GLOBAL MARKET FOR IMBRUVICA, THROUGH 2022 (\$ MILLIONS/%)</i>	88
Keytruda (Pembrolizumab; Merck)	88
BTD: October 27, 2014, November 2, 2015, April 18, 2016	88
Drug Class: Anti-PD-1 Monoclonal Antibody (Biologic)	89
Indication: Solid Tumors (Oncology)	89
Clinical Stage: Approved	89
Melanoma	89
KEYNOTE-001: Phase 1b	89
KEYNOTE-002: Phase 2	90
KEYNOTE-028 Study: Phase 1b	90
KEYNOTE-006 Study: Phase 3	90
NSCLC - First-Line KEYNOTE-010 Phase 2/3	90
Classical Hodgkin Lymphoma	91
Colorectal Cancer	91
Forecast	91
<i>TABLE 48 GLOBAL MARKET FOR KEYTRUDA, THROUGH 2022 (\$ MILLIONS/%)</i>	92
Lartruvo (Olaratumab; Eli Lilly)	92
BTD: August 6, 2015	92
Drug Class: Platelet Derived Growth Factor Receptor Alpha Antagonist (Small Molecule)	92
Indication: Soft Tissue Sarcoma	92
Clinical Stage: Approved	93
Forecast	93
<i>TABLE 49 GLOBAL MARKET FOR LARTRUVO, THROUGH 2022 (\$ MILLIONS/%)</i>	93
Lenvima/Kisplyx (Lenvatinib; Eisai)	93
BTD: August 6, 2015	93
Drug Class: Tyrosine Kinase Inhibitor (Small Molecule)	93
Indication: Thyroid Cancer (Oncology)	94
Clinical Stage: Phase 3	94
Forecast	94
<i>TABLE 50 GLOBAL MARKET FOR LENVIMA/KISPLYX, THROUGH 2022 (\$ MILLIONS/%)</i>	94
Lynparza (Olaparib; AstraZeneca)	95
BTD: January 27, 2016	95
Drug Class: Poly ADP-Ribose Polymerase Inhibitor (PARP Oncology)	95
Indication: Metastatic Castration-Resistant Prostate Cancer (mCRPC; Oncology)	95
Clinical Stage: Phase 2	95
Forecast	95

TOPIC	PAGE NO.
<i>TABLE 51 GLOBAL MARKET FOR LYNPARZA, THROUGH 2022 (\$ MILLIONS/%)</i>	96
Midostaurin (PKC412; Novartis)	96
BTD: February 19, 2016	96
Drug Class: Oral, Multi-Targeted Kinase Inhibitor (Small Molecule)	96
Indication: Acute Myeloid Leukemia (AML; Oncology)	96
Clinical Stage: Phase 3	96
Forecast	97
<i>TABLE 52 GLOBAL MARKET FOR MIDOSTAURIN, THROUGH 2022 (\$ MILLIONS/%)</i>	97
Opdivo (Nivolumab; BMS)	97
BTD: April 25, 2016, and June 27, 2016	97
Drug Class: PD-1 Inhibitor (Small Molecule)	97
Indication: Solid Tumors (Oncology)	98
Clinical Stage: Advanced Melanoma Checkmate 067: Phase 3	99
Checkmate 069: Phase 2	99
Bladder Cancer CheckMate-032:	99
Advanced Squamous Non-Small Cell Lung Cancer: CheckMate -017: Phase 3	99
CheckMate -063: Phase 2	99
Second-Line Treatment of Metastatic Non-Squamous NSCLC	100
Metastatic Renal Cell Carcinoma CheckMate 025 Trial: Phase 3	100
CheckMate-057: Phase 3	100
Forecast	101
<i>TABLE 53 GLOBAL MARKET FOR OPDIVO, THROUGH 2022 (\$ MILLIONS/%)</i>	101
Tagrisso (Osimertinib; AstraZeneca)	101
BTD Date; April 24, 2104	101
Drug Class: EGFR- Tyrosine Kinase Inhibitor (Small Molecule)	102
Indication: Non-Small-Cell Lung Cancer (Oncology)	102
Clinical Stage: Approved	102
Forecast	102
<i>TABLE 54 GLOBAL MARKET FOR TAGRISSO, SALES FORECASTS, THROUGH 2022 (\$ MILLIONS/%)</i>	103
Tafinlar/Mekinist (Dabrafenib/Trametinib; GlaxoSmithKline)	103
BTD: January 2014 (Monotherapy) and July 23, 2015 (Combination Therapy)	103
Drug Class: BRAF Inhibitor plus MEK Inhibitor (Biologic)	103
Indication: NSCLC (Oncology).	103
Clinical Stage: Approved	104
Monotherapy Trial	104
Combination Therapy Trial	104
Forecast	104
<i>TABLE 55 GLOBAL MARKET FOR TAFINLAR/MEKINIST, THROUGH 2022 (\$ MILLIONS/%)</i>	104
Tecentriq (Atezolizumab; Genentech/Roche)	105
BTD: January 23, 2014	105
Drug Class: Programmed Cell Death-1 Ligand 1 Monoclonal Antibody (Biologic)	105
Indication: Metastatic Urothelial Carcinoma (Oncology)	105
Clinical Stage: Approved	105

TOPIC	PAGE NO.
Forecast	106
<i>TABLE 56 GLOBAL MARKET FOR TECENTRIQ, THROUGH 2022 (\$ MILLIONS/%)</i>	106
Venclexta (Venetoclax; AbbVie/Roche/Genentech)	106
BTD: April 2015 and January 2016	106
Drug Class: Oral B-cell Lymphoma-2 Inhibitor (Small Molecule)	106
Indication: CLL (Oncology)	107
Clinical Stage: Approved	107
Forecast	107
<i>TABLE 57 GLOBAL MARKET FOR VENCLEXTA, THROUGH 2022 (\$ MILLIONS/%)</i>	108
Xalkori (Crizotinib; Pfizer)	108
BTD: August 26, 2011	108
Drug Class: Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Receptor Inhibitor (Small Molecule)	108
Indication: ALK+ NSCLC (Oncology)	108
Clinical Stage: Approved	109
First-Line Therapy - Study 1	109
Second-Line Therapy - Study 2	109
Forecast	109
<i>TABLE 58 GLOBAL MARKET FOR XALKORI, THROUGH 2022 (\$ MILLIONS/%)</i>	110
Zydelig (Idelalisib, Gilead Sciences)	110
BTD: November 18, 2013	110
Drug Class: Oral Phosphoinositide 3-Kinase (PI3K) Delta Inhibitor (Small Molecule)	110
Indication: CLL	110
Clinical Stage: Approved	110
Forecast	111
<i>TABLE 59 GLOBAL MARKET FOR ZYDELIG, THROUGH 2022 (\$ MILLIONS/%)</i>	111
Zykadia (Ceritinib; Novartis)	112
BTD: March 15, 2013	112
Drug Class: Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Receptor Inhibitor (Small Molecule)	112
Indication: ALK+ NSCLC (Oncology)	112
Clinical Stage: Approved	112
Forecast	112
<i>TABLE 60 GLOBAL MARKET FOR ZYKADIA, THROUGH 2022 (\$ MILLIONS/%)</i>	113
ONCOLOGY - BTD IN DEVELOPMENT	113
<i>TABLE 61 UNDER DEVELOPMENT ONCOLOGY BREAKTHROUGH THERAPY DESIGNATION DRUGS</i>	113
Abemaciclib (Eli Lilly)	116
BTD: August 8, 2015	116
Indication: Her2 Metastatic Breast Cancer (Oncology)	116
Drug Class: CDK4-6 Inhibitor (Small Molecule)	116
Clinical Stage: Phase 3	116
Forecast	117
<i>TABLE 62 GLOBAL MARKET FOR ABEMACICLIB, THROUGH 2022 (\$ MILLIONS/%)</i>	117
Avelumab (Merck KGaA/Pfizer)	117
BTD: November 18, 2015	117

TOPIC	PAGE NO.
Drug Class: Fully Human Monoclonal Antibody Targeting Programmed Death Ligand-1 (Biologic)	118
Indication: Metastatic Merkel Cell Carcinoma (Oncology)	118
Clinical Stage: Phase 3 NSCL/ Phase 2 MCC/ Phase 1 Solid Tumors	118
Forecast	118
TABLE 63 GLOBAL MARKET FOR AVELUMAB, THROUGH 2022 (\$ MILLIONS/%)	119
Brigatinib (AP26113; ARIAD Pharmaceuticals)	119
BTD: October 1, 2014	119
Drug Class: Oral Inhibitor of Anaplastic Lymphoma Kinase (ALK) Inhibitor (Small Molecule)	119
Indication: ALK+ NSCLC (Oncology)	119
Clinical Stage: Filed	120
Forecast	120
TABLE 64 GLOBAL MARKET FOR BRIGATINIB, THROUGH 2022 (\$ MILLIONS/%)	120
CTL019 (Novartis)	120
BTD: July 2014	120
Drug Class: Autologous Chimeric Antigen Receptor (CAR)- T Cell Therapy targeting CD19 (Biologic)	121
Indication: CLL	121
Clinical Stage: Phase 2	121
Forecast	122
TABLE 65 GLOBAL MARKET FOR CTL019, THROUGH 2022 (\$ MILLIONS/%)	122
CRS-207 and GVAX (Aduro Biotech)	122
BTD: 17 February, 2016	122
Drug Class: Tumor-Associated Antigen Mesothelin (Biologic)	122
Indication: Metastatic Pancreatic Cancer (Oncology)	122
Clinical Stage: Phase 2b	123
Forecast	123
TABLE 66 GLOBAL MARKET FOR CRS-207 AND GVAX PANCREAS, THROUGH 2022 (\$ MILLIONS/%)	123
Durvalumab (MEDI4736; AstraZeneca-MedImmune)	124
BTD: February 17, 2016	124
Drug Class: Humanized Monoclonal Antibody Targeting Programmed Death Ligand-1 (Biologic)	124
Indication: Metastatic Urothelial Bladder (Oncology)	124
Clinical Stage: Phase 3	124
Forecast	124
TABLE 67 GLOBAL MARKET FOR DURVALUMAB, THROUGH 2022 (\$ MILLIONS/%)	125
EBV-CTL (Atara and MSKCC)	125
BTD: February 3, 2015	125
Drug Class: Allogeneic Hematopoietic Cell Transplant (Biologic)	125
Indication: EBV-Associated Lymphoproliferative Disease (Oncology)	125
Clinical Stage: Phase 3	126
Forecast	126
TABLE 68 GLOBAL MARKET FOR EBV-CTL, THROUGH 2022 (\$ MILLIONS/%)	126
Entinostat (Syndax Pharmaceuticals)	126
BTD: September 11, 2013	126

TOPIC	PAGE NO.
Drug Class: Antibody Histone Deacetylase Inhibitor (Small Molecule)	127
<i>FIGURE 13 ENTINOSTAT MECHANISM OF ACTION</i>	127
Indication: Advanced HER2 Breast Cancer	127
Clinical Stage: Phase 3	128
Forecast	128
<i>TABLE 69 GLOBAL MARKET FOR ENTINOSTAT, THROUGH 2022 (\$ MILLIONS/%)</i>	129
Inotuzumab Ozogamicin (Pfizer, Celltech)	129
BTD: October 19, 2015	129
Drug Class: Antibody Drug Conjugate (ADC) mAb Targeting CD22 plusC Agent Inotuzumab (Biologic)	129
Indication: B-cell ALL	129
Clinical Stage: Phase 3	129
Forecast	130
<i>TABLE 70 GLOBAL MARKET FOR INOTUZUMAB OZOGAMICIN, THROUGH 2022 (\$ MILLIONS/%)</i>	130
JCAR015 (Juno Therapeutics)	130
BTD: November 24, 2014	130
Drug Class: Autologous Chimeric Antigen Receptor (CAR) - T Cell Therapy Targeting CD19 (Biologic)	131
Indication: Relapse-Refractory B-Cell ALL	131
Clinical Stage: Phase 1-2	131
Forecast	132
<i>TABLE 71 GLOBAL MARKET FOR JCAR015, THROUGH 2022 (\$ MILLIONS/%)</i>	132
KTE-C19 (Kite Pharma)	132
BTD: December 7, 2015	132
Drug Class: Allogenic Chimeric Antigen Receptor (CAR) - T Cell Therapy Targeting CD19 (Biologic)	133
Indication: Refractory, Diffuse Large B-Cell Lymphoma (DLBCL; Oncology)	133
Clinical Stage: Phase 2	133
Forecast	133
<i>TABLE 72 GLOBAL MARKET FOR KTE-C19, THROUGH 2022 (\$ MILLIONS/%)</i>	134
LOXO-101 (Loxo Oncology, Inc)	134
BTD: July 13, 2016	134
Drug Class: Pan Tropomyosin Receptor Kinase Inhibitor (Small Molecules)	134
Indication: Solid Tumors (Oncology)	134
Clinical Stage: Phase 2	135
Forecast	135
<i>TABLE 73 GLOBAL MARKET FOR LOXO-101, THROUGH 2022 (\$ MILLIONS/%)</i>	136
Nicord (Elbit Imaging/Gamida Cell)	136
BTD: October 11, 2016	136
Drug Class: Allogeneic Hematopoietic Cell Transplant (Biologic)	136
Indication: haematological malignancies (Oncology)	136
Clinical Stage: Phases 1 and 2	137
Forecast	137
<i>TABLE 74 GLOBAL MARKET FOR NICORD, THROUGH 2022 (\$ MILLIONS/%)</i>	137
Olmudinib (Boehringer Ingelheim)	138

TOPIC	PAGE NO.
BTD: December 21, 2015	138
Drug Class: Fully Human Monoclonal Antibody Targeting Programmed Death Ligand-1 (Biologic)	138
Indication: T790M Mutation NSCLC (Oncology)	138
Clinical Stage: Phases 1 and 2 (Approved in South Korea)	138
Forecast	139
<i>TABLE 75 GLOBAL MARKET FOR OLMUTINIB, THROUGH 2022 (\$ MILLIONS/%)</i>	139
NY-ESO Peptide (Affinity Enhanced T-Cell Therapy; Adaptimmune)	139
BTD: February 9, 2016	139
Drug class: T-cell Therapy (TCR; Biologic)	140
Indication: Synovial Sarcoma (Oncology)	140
Clinical Stage: Phases 1 and 2	140
Forecast	140
<i>TABLE 76 GLOBAL MARKET FOR NY-ESO, THROUGH 2022 (\$ MILLIONS/%)</i>	141
Pexidartinib (Daiichi Sankyo/Plexxikon)	141
BTD: October 30, 2015	141
Drug Class: Multitargeted Receptor Tyrosine Kinase (RTK) Inhibitor (Small Molecule)	141
Indication: Tenosynovial Giant Cell Tumor (TGCT; Oncology)	141
Clinical Stage: Phase 1	142
Forecast	142
<i>TABLE 77 GLOBAL MARKET FOR PEXIDARTINIB, THROUGH 2022 (\$ MILLIONS/%)</i>	142
Pracinostat (MEI Pharma)	143
BTD: August 1, 2016	143
Drug Class: HDAC Inhibitor (Small Molecule)	143
Indication: AML (Oncology)	143
Clinical Stage: Phase 2	143
Forecast	143
<i>TABLE 78 GLOBAL MARKET FOR PRACINOSTAT, THROUGH 2022 (\$ MILLIONS/%)</i>	144
PVS-RIPO (Duke Medicine)	144
BTD: May 16, 2016	144
Drug Class: Genetically Modified Poliovirus (Biologic)	144
Indication: Glioblastoma (Oncology)	145
Clinical Stage: Phase 1	145
Forecast	145
<i>TABLE 79 GLOBAL MARKET FOR PVS-RIPO, THROUGH 2022 (\$ MILLIONS/%)</i>	145
Ribociclib (LEE011; Novartis)	146
BTD: August 3, 2016	146
Indication: Her2 Metastatic Breast Cancer (Oncology)	146
Drug Class: CDK4-6 Inhibitor (Small Molecule)	146
Clinical Stage: Phase 3	146
Forecast	146
<i>TABLE 80 GLOBAL MARKET FOR RIBOCICLIB, THROUGH 2022 (\$ MILLIONS/%)</i>	147
Rintega (Celldex)	147
BTD: February 23, 2015	147
Indication: Glioblastoma (Oncology)	147
Drug class: Cancer Vaccine (Biologic)	147
Clinical Stage: Discontinued	147

TOPIC	PAGE NO.
Forecast	148
<i>TABLE 81 GLOBAL MARKET FOR RINTEGA, THROUGH 2022 (\$ MILLIONS/%)</i>	148
Rociletinib (Clovis Oncology)	148
BTD: August 3, 2016	148
Indication: Her2 Metastatic Breast Cancer (Oncology)	148
Drug Class: Epidermal Growth Factor Receptor Inhibitor (Small Molecule)	149
Indication: Non-small Cell Lung Cancer (Oncology)	149
Clinical Stage: Discontinued	149
Forecast	149
<i>TABLE 82 GLOBAL MARKET FOR ROCILETINIB, THROUGH 2022 (\$ MILLIONS/%)</i>	149
Rucaparib (Clovis Pharmaceuticals)	150
BTD: April 2015	150
Drug Class: Oral PARP Inhibitor (PARP; Small Molecule)	150
Indication: Ovarian Cancer (Oncology)	150
Clinical Stage: Phase 2	151
Forecast	151
<i>TABLE 83 GLOBAL MARKET FOR RUCAPARIB, THROUGH 2022 (\$ MILLIONS/%)</i>	151
Sacituzumab Govitecan (IMMU-132; Immunomedics)	152
BTD: February 8, 2016	152
Drug Class: Antibody-Drug Conjugate (ADC; Biologic)	152
Indication: Triple-Negative Breast Cancer (TNBC; Oncology)	152
Clinical Stage: Phase 2	152
Forecast	153
<i>TABLE 84 GLOBAL MARKET FOR SACITUZUMAB GOVITECAN, THROUGH 2022 (\$ Millions/%)</i>	153
Volasertib (Boehringer Ingelheim)	153
BTD: September 17, 2013	153
Drug Class: Polo-Like Kinase (Plk) Inhibitor (Biologic)	153
Indication: Acute Myeloid Leukemia (AML)	154
Clinical Stage: Phase 3	154
Forecast	155
<i>TABLE 85 GLOBAL MARKET FOR VOLASERTIB, THROUGH 2022 (\$ MILLIONS/%)</i>	155
Vyxeos (Cpx-351; Celator Pharmaceuticals-Jazz Pharmaceuticals)	155
BTD: May 19, 2016	155
Drug Class: Nano-Scale Liposomal Formulation of Cytarabine: Daunorubicin (Small Molecule)	155
Indication: AML	156
Clinical Stage: Phase 3	156
Forecast	156
<i>TABLE 86 GLOBAL MARKET FOR VYXEOS, THROUGH 2022 (\$ MILLIONS/%)</i>	157
RARE DISEASES	157
<i>FIGURE 14 RARE DISEASE BREAKTHROUGH THERAPY DESIGNATION DRUGS, BY STAGE, 2016</i>	158
RARE DISEASES - BTD APPROVED	158
<i>TABLE 87 FDA APPROVED RARE DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS, 2015-2016</i>	159
<i>TABLE 88 GLOBAL MARKET FOR RARE DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)</i>	159

TOPIC	PAGE NO.
Ilaris (Canak Inumab, Novartis)	160
BTD: April 27, 2016	160
Drug Class: Human Monoclonal Antibody Targeting Interleukin-1 Beta (Biologic)	160
Indication: PFS, TRAPS and FMF (Rare Disease)	160
Clinical Stage: Approved	160
Forecast	161
<i>TABLE 89 GLOBAL MARKET FOR ILARIS, THROUGH 2022 (\$ MILLIONS/%)</i>	161
Kanuma (Sebelipase Alfa; Alexion Pharmaceuticals)	161
BTD May 20, 2013	161
Drug Class: Enzyme Replacement Therapy (Biologic)	161
Indication: Lysosomal Acid Lipase Deficiency (Rare Disease)	161
Clinical Stage: Approved	162
Forecast	162
<i>TABLE 90 GLOBAL MARKET FOR KANUMA, THROUGH 2022 (\$ MILLIONS/%)</i>	162
Strensiq (Asfotase Alfa; Alexion Pharmaceuticals)	162
BTD: May 28, 2013	162
Drug Class: Enzyme Replacement Therapy (Biologic)	163
Indication: Hypophosphatasia (Rare Disease)	163
Clinical Stage: Approved	163
Forecast	163
<i>TABLE 91 GLOBAL MARKET FOR STRENSIQ, THROUGH 2022 (\$ MILLIONS/%)</i>	163
RARE DISEASES - BTD IN DEVELOPMENT	164
<i>TABLE 92 UNDER DEVELOPMENT RARE DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS, 2013-2016</i>	164
ALXN1101 (Alexion Pharmaceuticals)	164
BTD: October 24, 2013	164
Drug Class: Enzyme Co-Factor Replacement Therapy (Biologic)	165
Indication: Molybdenum Cofactor Deficiency (MoCD; Rare Diseases)	165
Clinical Stage: Phase 2 and Phase 3	165
Forecast	165
<i>TABLE 93 GLOBAL MARKET FOR ALXN-1101, THROUGH 2022 (\$ MILLIONS/%)</i>	165
Firdapse (Amifampridine; Catalyst Pharmaceuticals)	166
BTD: February 22, 2016	166
Drug Class: Potassium channel blocker (Small Molecule)	166
Indication: Lambert-Eaton Myasthenic Syndrome (LEMS; Rare Disease)	166
Clinical Stage: Phase 3	166
Forecast	166
<i>TABLE 94 GLOBAL MARKET FOR FIRDAPSE, THROUGH 2022 (\$ MILLIONS/%)</i>	167
Olipudase Alfa (Sanofi Genzyme)	167
BTD: June 4, 2014	167
Drug Class: Enzyme Replacement Therapy (Biologic)	167
Indication: Acid Sphingomyelinase Deficiency-Niemann-Pick Disease Type B	167
Clinical Stage: Phase 2 and Phase 3	168
Forecast	168

TOPIC	PAGE NO.
<i>TABLE 95 GLOBAL MARKET FOR OLIPUDASE ALFA, THROUGH 2022 (\$ MILLIONS/%)</i>	168
Zorblisa (SD-101; -Amicus Therapeutics /Scioderm)	169
BTD: April 23, 2013	169
Drug Class: Topical Cream (Small Molecule)	169
Indication: Epidermolysis Bullosa (Rare Disease)	169
Clinical Stage: Phase 2	169
Forecast	169
<i>TABLE 96 GLOBAL MARKET FOR ZORBLISA, THROUGH 2022 (\$ MILLIONS/%)</i>	170
Setmelanotide (RM-493; Rhythm Pharmaceuticals)	170
BTD: January 7, 2016	170
Drug Class: Melanocortin-4 Receptor (MC4R) Agonist (Small Molecule)	170
Indication: Pro-Opiomelanocortin (POMC) Deficiency Obesity (Rare Diseases)	170
Clinical Stage: Phase 2	170
Forecast	171
<i>TABLE 97 GLOBAL MARKET FOR SETMELANOTIDE, THROUGH 2022 (\$ MILLIONS)</i>	171
VTS-270 (Vtesse Pharmaceuticals)	171
BTD: January 6, 2016	171
Drug Class: 2-Hydroxypropyl-B-Cyclodextrin (Small Molecule)	171
Indication: Niemann-Pick Type C1 (NPC) Disease (Rare Disease)	172
Clinical Stage: Phase 2 and Phase 3	172
Forecast	172
<i>TABLE 98 GLOBAL MARKET FOR VTS-270, THROUGH 2022 (\$ MILLIONS/%)</i>	172
OTHER DISEASES	173
<i>FIGURE 15 OTHER DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS, BY STAGE, 2016 (NUMBER)</i>	173
OTHER - BTD APPROVED	173
<i>TABLE 99 FDA APPROVED OTHER BREAKTHROUGH THERAPY DESIGNATION DRUGS, 2015</i>	174
<i>TABLE 100 GLOBAL MARKET FOR OTHER DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)</i>	174
Rapamune (Sirolimus, Pfizer)	174
BTD Date: May 28, 2015	174
Drug Class: Macrolide Lactam Immunosuppressant (Small Molecule)	175
Indication: Lymphangioliomyomatosis (LAM)	175
Clinical Stage: Approved	175
Forecast	175
<i>TABLE 101 GLOBAL MARKET FOR RAPAMUNE BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)</i>	175
Lucentis (Ranibizumab Genentech-Roche)	176
BTD Date: December 15, 2014	176
Drug Class: (EGF Inhibitor (Biologic)	176
Indication Diabetic Retinopathy (DR)	176
Clinical Stage: Approved	176
Forecast	176
<i>TABLE 102 GLOBAL MARKET FOR LUCENTIS BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)</i>	177

TOPIC	PAGE NO.
Eylea (Aflibercept; Bayer)	177
BTD Date: September 16, 2014	177
Drug Class: VEGF Fusion Protein (Biologic)	177
Indication Diabetic Retinopathy (DR)	177
Clinical Stage: Approved	177
Forecast	178
<i>TABLE 103 GLOBAL MARKET FOR EYLEA BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)</i>	178
OTHER DISEASES - BTD IN DEVELOPMENT	178
<i>TABLE 104 OTHER DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS AWAITING APPROVAL, 2015-2022</i>	179
Dupilumab (Sanofi-Regeneron)	179
BTD Date: November 20, 2014	179
Drug Class: IL-4 mAb (Biologic)	179
Indication: Severe Atopic Dermatitis	179
Clinical Stage: Filed	180
Forecast	180
<i>TABLE 105 GLOBAL MARKET FOR DUPILUMAB BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)</i>	181
AR101 (Aimmune Therapeutics)	181
BTD Date: June 18, 2015	181
Indication: Peanut Allergen (Small Molecule)	181
Clinical Stage: Phase 3	181
Forecast	181
<i>TABLE 106 GLOBAL MARKET FOR AR101 BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)</i>	182
Ocaliva (Obeticholic acid; Intercept Pharmaceuticals)	182
BTD Date: January 1, 2015	182
Drug Class: Farnesoid X Receptor Agonist (Small Molecule)	182
Indication: Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis (Rare Disease)	182
Clinical Stage: Phase 3	183
Forecast	183
<i>TABLE 107 GLOBAL MARKET FOR OCALIVA BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)</i>	183
Viaskin Peanut (DBV Technologies)	184
BTD: April 9, 2015	184
Drug Class: Peanut Allergen (Small Molecule)	184
Indication: Peanut Allergen (Small Molecule)	184
Clinical Stage: Phase 2	184
Forecast	184
<i>TABLE 108 GLOBAL MARKET FOR VIASKIN PEANUT BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)</i>	185
CHAPTER 5 IMPLICATIONS OF BREAKTHROUGH THERAPY DESIGNATION ON BUSINESS STRATEGY	187
INTRODUCTION	187
<i>FIGURE 16 COMPARISON OF APPROVAL TIMES STANDARD VERSUS BREAKTHROUGH DESIGNATION (MONTHS)</i>	187

TOPIC	PAGE NO.
IMPLICATIONS FOR CLINICAL DEVELOPMENT	188
STRATEGIES FOR EXPEDITING CLINICAL DEVELOPMENT	189
Process and Formulation Development	189
Process Validation	190
Analytical Development	191
Availability of Stability Data	191
IMPLICATIONS FOR MANUFACTURING	192
Companion Diagnostics	193
STRATEGIES FOR EXPEDITING MANUFACTURING CAPABILITIES	193
MANAGING TECHNICAL RISKS VERSUS PATIENT BENEFIT	194
LOOKING AHEAD	195
CHAPTER 6 REGULATORY IMPLICATIONS AND BREAKTHROUGH THERAPY DESIGNATION	197
EXPEDITED PROGRAMS	197
<i>TABLE 109 AN OVERVIEW OF THE KEY FEATURES OF THE FDA'S EXPEDITED PROGRAMS</i>	198
REGULATORY PATHWAYS	198
<i>TABLE 110 AN OVERVIEW OF THE FDA'S EXPEDITED DEVELOPMENT AND REVIEW PROGRAMS</i>	199
FAST TRACK DESIGNATION	200
Qualifying Criteria	200
Serious Condition	201
Demonstrates the Potential to Address Unmet Medical Need	201
Key Features of Fast Track Designation	201
BREAKTHROUGH THERAPY DESIGNATION	202
Qualifying Criteria	202
Key Features	205
Intensive Guidance on an Efficient Drug Development Program, Beginning as early as Phase 1	205
<i>TABLE 111 BREAKTHROUGH THERAPIES CONSIDERATIONS: DRUG DEVELOPMENT</i>	205
Organizational Commitment Involving Senior Managers	206
Submission of Portions of an Application (Rolling Review)	206
<i>TABLE 112 BREAKTHROUGH THERAPY CONSIDERATIONS: MARKETING APPLICATION REVIEW</i>	206
Other Actions to Expedite Review	206
When to Make a BTM Request Submission	207
The BTM Review Process	207
<i>FIGURE 17 COMPARISON OF STANDARD AND BREAKTHROUGH THERAPY APPROVAL TIMES (MONTHS)</i>	207
Rescinding BTM Status	208
ACCELERATED APPROVAL	209
Qualifying Criteria	209
ACCELERATED APPROVAL ENDPOINTS	210
Conditions of Accelerated Approval	211
PRIORITY REVIEW DESIGNATION	212
Qualifying Criteria	212
Key Features	213
DRUGS GRANTED BREAKTHROUGH THERAPY DESIGNATION	213

TOPIC	PAGE NO.
<i>TABLE 113 CDER BREAKTHROUGH THERAPY DESIGNATION REQUESTS RECEIVED BY FISCAL YEAR COHORT: JULY 9, 2012*-SEPTEMBER 30, 2015</i>	214
<i>TABLE 114 CDER BREAKTHROUGH THERAPY DESIGNATION REQUESTS RECEIVED BY FISCAL YEAR COHORT: OCTOBER 1, 2015-SEPTEMBER 30, 2016</i>	214
<i>TABLE 115 CDER BREAKTHROUGH THERAPY DESIGNATION APPROVALS DATA AS OF DECEMBER 31, 2015</i>	215
<i>TABLE 116 CUMULATIVE CBER BREAKTHROUGH THERAPY DESIGNATION REQUESTS RECEIVED BY FISCAL YEAR COHORT: JULY 9, 2012*-DECEMBER 31, 2015</i>	216
<i>TABLE 117 CBER BREAKTHROUGH THERAPY DESIGNATION REQUESTS RECEIVED BY FISCAL YEAR COHORT: OCTOBER 1, 2015-SEPTEMBER 30, 2016</i>	217
<i>TABLE 118 CUMULATIVE CBER BREAKTHROUGH THERAPY APPROVAL DATA AS OF SEPTEMBER 30, 2016</i>	217
<i>TABLE 119 MOST RECENTLY ANNOUNCED BREAKTHROUGH THERAPY DESIGNATIONS DATA AS OF FEBRUARY 29, 2016</i>	218
SIGNIFICANCE OF BTD FOR THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES	220
CHAPTER 7 COMPANY PROFILES	223
ABBVIE INC.	223
ACADIA PHARMACEUTICALS INC.	223
ADAPTIMMUNE THERAPEUTICS PLC	224
ADURO BIOTECH INC.	224
AIMMUNE THERAPEUTICS INC.	225
ALEXION PHARMACEUTICALS INC.	225
ALLERGAN PLC	226
AMGEN INC.	226
ANATARA LIFESCIENCES LIMITED	227
ARIAD PHARMACEUTICALS INC.	227
ASTRAZENECA PLC	228
AVEXIS INC.	229
BOEHRINGER INGELHEIM GMBH	229
CELLEX THERAPEUTICS INC.	230
CLOVIS ONCOLOGY INC.	230
DAIICHI SANKYO COMPANY, LIMITED	231
DBV TECHNOLOGIES	231
EISAI CO. LTD.	232
ELI LILLY AND COMPANY	232
EXELIXIS INC.	233
F. HOFFMANN-LA ROCHE LTD.	234
GILEAD SCIENCES INC.	234
GLAXOSMITHKLINE PLC	235
IMMUNOMEDICS INC.	235
INDIVIDOR PLC	236
JAZZ PHARMACEUTICALS	236
JOHNSON & JOHNSON	237
JUNO THERAPEUTICS INC.	237
KITE PHARMA INC.	238
MERCK & CO. INC.	238

TOPIC	PAGE NO.
MERCK KGAA	239
NOVARTIS AG	239
PFIZER INC.	240
PHARMACYCLICS INC.	241
PROGENICS PHARMACEUTICALS INC.	242
REGENERON PHARMACEUTICALS INC.	242
RHYTHM PHARMACEUTICALS INC.	243
SYNDAX PHARMACEUTICALS INC.	243
SYNEURX INTERNATIONAL CORPORATION	244
TEVA PHARMACEUTICALS INC.	244
TREVENA INC.	244
VERTEX PHARMACEUTICALS INC.	245
VTESSE INC.	245
WELLSTAT THERAPEUTICS CORPORATION	246
CHAPTER 8 REFERENCES	248
CHAPTER 3	248
CHAPTER 4	249
CHAPTER 5	249
CHAPTER 6	250
CHAPTER 9 ACRONYMS	255
CHAPTER 10 ENDNOTES	258

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR BREAKTHROUGH THERAPY DESIGNATION DRUGS, BY THERAPY, THROUGH 2022 (\$ MILLIONS)	7
TABLE 1 CDER BREAKTHROUGH THERAPY DESIGNATION REQUESTS RECEIVED BY FISCAL YEAR COHORT: JULY 9, 2012*-SEPTEMBER 30, 2015	14
TABLE 2 CBER BREAKTHROUGH THERAPY REQUESTS FOR FINAL YEAR, OCTOBER 1, 2014-SEPTEMBER 30, 2015	14
TABLE 3 DRUGS GRANTED PRIME DESIGNATIONS, MARCH 7, 2016-AUGUST 24, 2016	18
TABLE 4 GLOBAL MARKET FOR CV BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)	25
TABLE 5 FDA APPROVED CV BREAKTHROUGH THERAPY DESIGNATION DRUGS	25
TABLE 6 GLOBAL MARKET FOR PROMACTA, THROUGH 2022 (\$ MILLIONS/%)	27
TABLE 7 GLOBAL MARKET FOR PRAXBIND, THROUGH 2022 (\$ MILLIONS/%)	28
TABLE 8 UNDER DEVELOPMENT CV BREAKTHROUGH THERAPY DESIGNATION DRUGS	28
TABLE 9 GLOBAL MARKET FOR REASANZ, THROUGH 2022 (\$ MILLIONS/%)	30
TABLE 10 GLOBAL MARKET FOR ACTEMRA/ROACTEMRA, THROUGH 2022 (\$ MILLIONS/%)	32
TABLE 11 GLOBAL MARKET FOR CNS BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)	34
TABLE 12 FDA APPROVED CNS BREAKTHROUGH THERAPY DESIGNATION DRUGS	34
TABLE 13 GLOBAL MARKET FOR NUPLAZID, THROUGH 2022 (\$ MILLIONS/%)	35
TABLE 14 UNDER DEVELOPMENT CNS BREAKTHROUGH THERAPY DESIGNATION DRUGS	36
TABLE 15 GLOBAL MARKET FOR DEUTETRABENAZINE ER, THROUGH 2022 (\$ MILLIONS/%)	38
TABLE 16 GLOBAL MARKET FOR INGREZZA, THROUGH 2022 (\$ MILLIONS/%)	40
TABLE 17 GLOBAL MARKET FOR OF OFATUMUMAB, THROUGH 2022 (\$ MILLIONS/%)	41
TABLE 18 GLOBAL MARKET FOR OLICERIDINE, THROUGH 2022 (\$ MILLIONS/%)	43
TABLE 19 GLOBAL MARKET FOR RAPASTINEL, THROUGH 2022 (\$ MILLIONS/%)	45
TABLE 20 GLOBAL MARKET FOR SEPRANOLONE, THROUGH 2022 (\$ MILLIONS/%)	46
TABLE 21 GLOBAL MARKET FOR SND-13, THROUGH 2022 (\$ MILLIONS/%)	47
TABLE 22 GLOBAL MARKET FOR AVXS-101, THROUGH 2022 (\$ MILLIONS/%)	49
TABLE 23 GLOBAL MARKET FOR ESKETAMINE, THROUGH 2022 (\$ MILLIONS/%)	50
TABLE 24 GLOBAL MARKET FOR RBP-8000, THROUGH 2022 (\$ MILLIONS/%)	51
TABLE 25 GLOBAL MARKET FOR INFECTIOUS DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)	53
TABLE 26 FDA APPROVED INFECTIOUS DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS, 2016	53
TABLE 27 GLOBAL MARKET FOR SOLVADI, THROUGH 2022 (\$ MILLIONS/%)	55
TABLE 28 GLOBAL MARKET FOR EPCLUSA, THROUGH 2022 (\$ MILLIONS/%)	56
TABLE 29 GLOBAL MARKET FOR VIEKERA/TECHNIVIE, THROUGH 2022 (\$ MILLIONS/%)	58
TABLE 30 GLOBAL MARKET FOR ZEPATIER, THROUGH 2022 (\$ MILLIONS/%)	59
TABLE 31 GLOBAL MARKET FOR HARVONI, THROUGH 2022 (\$ MILLIONS/%)	61
TABLE 32 UNDER DEVELOPMENT INFECTIOUS DISEASE BREAKTHROUGH THERAPY DESIGNATION DRUGS, 2016	61
TABLE 33 GLOBAL MARKET FOR ARIKAYCE, THROUGH 2022 (\$ MILLIONS/%)	63
TABLE 34 GLOBAL MARKET FOR FOSTEMSAVIR, THROUGH 2022 (\$ MILLIONS/%)	64
TABLE 35 GLOBAL MARKET FOR GLECAPREVIR/PIBRENTASVIR, THROUGH 2022 (\$ MILLIONS/%)	65

TABLE HEADING	PAGE NO.
TABLE 36 GLOBAL MARKET FOR IBALIZUMAB, THROUGH 2022 (\$ MILLIONS/%)	67
TABLE 37 GLOBAL MARKET FOR TAFENOQUINE, THROUGH 2022 (\$ MILLIONS/%)	68
TABLE 38 GLOBAL MARKET FOR V920, THROUGH 2022 (\$ MILLIONS/%)	69
TABLE 39 GLOBAL MARKET FOR ONCOLOGY BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)	72
TABLE 40 FDA APPROVED ONCOLOGY BREAKTHROUGH THERAPY DESIGNATION DRUGS, 2013-2015	72
TABLE 41 GLOBAL MARKET FOR ALENCENSA, THROUGH 2022 (\$ MILLIONS/%)	76
TABLE 42 GLOBAL MARKET FOR ARZERRA, THROUGH 2022 (\$ MILLIONS/%)	78
TABLE 43 GLOBAL MARKET FOR BLINCYTO, THROUGH 2022 (\$ MILLIONS/%)	80
TABLE 44 GLOBAL MARKET FOR DARZALEX, THROUGH 2022 (\$ MILLIONS/%)	82
TABLE 45 GLOBAL MARKET FOR GAZYVA, THROUGH 2022 (\$ MILLIONS/%)	83
TABLE 46 GLOBAL MARKET FOR IBRANCE, THROUGH 2022 (\$ MILLIONS/%)	86
TABLE 47 GLOBAL MARKET FOR IMBRUVICA, THROUGH 2022 (\$ MILLIONS/%)	88
TABLE 48 GLOBAL MARKET FOR KEYTRUDA, THROUGH 2022 (\$ MILLIONS/%)	92
TABLE 49 GLOBAL MARKET FOR LARTRUVO, THROUGH 2022 (\$ MILLIONS/%)	93
TABLE 50 GLOBAL MARKET FOR LENVIMA/KISPLYX, THROUGH 2022 (\$ MILLIONS/%)	94
TABLE 51 GLOBAL MARKET FOR LYNPARZA, THROUGH 2022 (\$ MILLIONS/%)	96
TABLE 52 GLOBAL MARKET FOR MIDOSTAURIN, THROUGH 2022 (\$ MILLIONS/%)	97
TABLE 53 GLOBAL MARKET FOR OPDIVO, THROUGH 2022 (\$ MILLIONS/%)	101
TABLE 54 GLOBAL MARKET FOR TAGRISSO, SALES FORECASTS, THROUGH 2022 (\$ MILLIONS/%)	103
TABLE 55 GLOBAL MARKET FOR TAFINLAR/MEKINIST, THROUGH 2022 (\$ MILLIONS/%)	104
TABLE 56 GLOBAL MARKET FOR TECENTRIQ, THROUGH 2022 (\$ MILLIONS/%)	106
TABLE 57 GLOBAL MARKET FOR VENCLEXTA, THROUGH 2022 (\$ MILLIONS/%)	108
TABLE 58 GLOBAL MARKET FOR XALKORI, THROUGH 2022 (\$ MILLIONS/%)	110
TABLE 59 GLOBAL MARKET FOR ZYDELIG, THROUGH 2022 (\$ MILLIONS/%)	111
TABLE 60 GLOBAL MARKET FOR ZYKADIA, THROUGH 2022 (\$ MILLIONS/%)	113
TABLE 61 UNDER DEVELOPMENT ONCOLOGY BREAKTHROUGH THERAPY DESIGNATION DRUGS	113
TABLE 62 GLOBAL MARKET FOR ABEMACICLIB, THROUGH 2022 (\$ MILLIONS/%)	117
TABLE 63 GLOBAL MARKET FOR AVELUMAB, THROUGH 2022 (\$ MILLIONS/%)	119
TABLE 64 GLOBAL MARKET FOR BRIGATINIB, THROUGH 2022 (\$ MILLIONS/%)	120
TABLE 65 GLOBAL MARKET FOR CTL019, THROUGH 2022 (\$ MILLIONS/%)	122
TABLE 66 GLOBAL MARKET FOR CRS-207 AND GVAX PANCREAS, THROUGH 2022 (\$ MILLIONS/%)	123
TABLE 67 GLOBAL MARKET FOR DURVALUMAB, THROUGH 2022 (\$ MILLIONS/%)	125
TABLE 68 GLOBAL MARKET FOR EBV-CTL, THROUGH 2022 (\$ MILLIONS/%)	126
TABLE 69 GLOBAL MARKET FOR ENTINOSTAT, THROUGH 2022 (\$ MILLIONS/%)	129
TABLE 70 GLOBAL MARKET FOR INOTUZUMAB OZOGAMICIN, THROUGH 2022 (\$ MILLIONS/%)	130
TABLE 71 GLOBAL MARKET FOR JCAR015, THROUGH 2022 (\$ MILLIONS/%)	132
TABLE 72 GLOBAL MARKET FOR KTE-C19, THROUGH 2022 (\$ MILLIONS/%)	134
TABLE 73 GLOBAL MARKET FOR LOXO-101, THROUGH 2022 (\$ MILLIONS/%)	136
TABLE 74 GLOBAL MARKET FOR NICORD, THROUGH 2022 (\$ MILLIONS/%)	137
TABLE 75 GLOBAL MARKET FOR OLMUTINIB, THROUGH 2022 (\$ MILLIONS/%)	139
TABLE 76 GLOBAL MARKET FOR NY-ESO, THROUGH 2022 (\$ MILLIONS/%)	141
TABLE 77 GLOBAL MARKET FOR PEXIDARTINIB, THROUGH 2022 (\$ MILLIONS/%)	142
TABLE 78 GLOBAL MARKET FOR PRACINOSTAT, THROUGH 2022 (\$ MILLIONS/%)	144

TABLE HEADING	PAGE NO.
TABLE 79 GLOBAL MARKET FOR PVS-RIPO, THROUGH 2022 (\$ MILLIONS/%)	145
TABLE 80 GLOBAL MARKET FOR RIBOCICLIB, THROUGH 2022 (\$ MILLIONS/%)	147
TABLE 81 GLOBAL MARKET FOR RINTEGA, THROUGH 2022 (\$ MILLIONS/%)	148
TABLE 82 GLOBAL MARKET FOR ROCILETINIB, THROUGH 2022 (\$ MILLIONS/%)	149
TABLE 83 GLOBAL MARKET FOR RUCAPARIB, THROUGH 2022 (\$ MILLIONS/%)	151
TABLE 84 GLOBAL MARKET FOR SACITUZUMAB GOVITECAN, THROUGH 2022 (\$ MILLIONS/%)	153
TABLE 85 GLOBAL MARKET FOR VOLASERTIB, THROUGH 2022 (\$ MILLIONS/%)	155
TABLE 86 GLOBAL MARKET FOR VYXEOS, THROUGH 2022 (\$ MILLIONS/%)	157
TABLE 87 FDA APPROVED RARE DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS, 2015-2016	159
TABLE 88 GLOBAL MARKET FOR RARE DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)	159
TABLE 89 GLOBAL MARKET FOR ILARIS, THROUGH 2022 (\$ MILLIONS/%)	161
TABLE 90 GLOBAL MARKET FOR KANUMA, THROUGH 2022 (\$ MILLIONS/%)	162
TABLE 91 GLOBAL MARKET FOR STRENSIQ, THROUGH 2022 (\$ MILLIONS/%)	163
TABLE 92 UNDER DEVELOPMENT RARE DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS, 2013-2016	164
TABLE 93 GLOBAL MARKET FOR ALXN-1101, THROUGH 2022 (\$ MILLIONS/%)	165
TABLE 94 GLOBAL MARKET FOR FIRDAPSE, THROUGH 2022 (\$ MILLIONS/%)	167
TABLE 95 GLOBAL MARKET FOR OLIPUDASE ALFA, THROUGH 2022 (\$ MILLIONS/%)	168
TABLE 96 GLOBAL MARKET FOR ZORBLISA, THROUGH 2022 (\$ MILLIONS/%)	170
TABLE 97 GLOBAL MARKET FOR SETMELANOTIDE, THROUGH 2022 (\$ MILLIONS)	171
TABLE 98 GLOBAL MARKET FOR VTS-270, THROUGH 2022 (\$ MILLIONS/%)	172
TABLE 99 FDA APPROVED OTHER BREAKTHROUGH THERAPY DESIGNATION DRUGS, 2015	174
TABLE 100 GLOBAL MARKET FOR OTHER DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)	174
TABLE 101 GLOBAL MARKET FOR RAPAMUNE BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)	175
TABLE 102 GLOBAL MARKET FOR LUCENTIS BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)	177
TABLE 103 GLOBAL MARKET FOR EYLEA BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)	178
TABLE 104 OTHER DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS AWAITING APPROVAL, 2015-2022	179
TABLE 105 GLOBAL MARKET FOR DUPILUMAB BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)	181
TABLE 106 GLOBAL MARKET FOR AR101 BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)	182
TABLE 107 GLOBAL MARKET FOR OCALIVA BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)	183
TABLE 108 GLOBAL MARKET FOR VIASKIN PEANUT BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022 (\$ MILLIONS/%)	185
TABLE 109 AN OVERVIEW OF THE KEY FEATURES OF THE FDA'S EXPEDITED PROGRAMS	198
TABLE 110 AN OVERVIEW OF THE FDA'S EXPEDITED DEVELOPMENT AND REVIEW PROGRAMS	199
TABLE 111 BREAKTHROUGH THERAPIES CONSIDERATIONS: DRUG DEVELOPMENT	205
TABLE 112 BREAKTHROUGH THERAPY CONSIDERATIONS: MARKETING APPLICATION REVIEW	206

TABLE HEADING	PAGE NO.
TABLE 113 CDER BREAKTHROUGH THERAPY DESIGNATION REQUESTS RECEIVED BY FISCAL YEAR COHORT: JULY 9, 2012*-SEPTEMBER 30, 2015	214
TABLE 114 CDER BREAKTHROUGH THERAPY DESIGNATION REQUESTS RECEIVED BY FISCAL YEAR COHORT: OCTOBER 1, 2015-SEPTEMBER 30, 2016	214
TABLE 115 CDER BREAKTHROUGH THERAPY DESIGNATION APPROVALS DATA AS OF DECEMBER 31, 2015	215
TABLE 116 CUMULATIVE CBER BREAKTHROUGH THERAPY DESIGNATION REQUESTS RECEIVED BY FISCAL YEAR COHORT: JULY 9, 2012*-DECEMBER 31, 2015	216
TABLE 117 CBER BREAKTHROUGH THERAPY DESIGNATION REQUESTS RECEIVED BY FISCAL YEAR COHORT: OCTOBER 1, 2015-SEPTEMBER 30, 2016	217
TABLE 118 CUMULATIVE CBER BREAKTHROUGH THERAPY APPROVAL DATA AS OF SEPTEMBER 30, 2016	217
TABLE 119 MOST RECENTLY ANNOUNCED BREAKTHROUGH THERAPY DESIGNATIONS DATA AS OF FEBRUARY 29, 2016	218

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR BREAKTHROUGH THERAPY DESIGNATION DRUGS, BY THERAPY, 2015-2022 (\$ MILLIONS)	7
FIGURE 1 BREAKTHROUGH THERAPY REQUESTS GRANTED BY DIVISION, 2015* (%)	15
FIGURE 2 PRIME SCHEME APPLICATIONS AND ELIGIBILITY	16
FIGURE 3 PRIME DRUG BY TYPE OF APPLICATION AND THERAPEUTIC AREA	17
FIGURE 4 PRIME DRUG APPLICATIONS, THERAPEUTIC AREA	18
FIGURE 5 FDA APPROVALS, BREAKTHROUGH THERAPY DESIGNATION AND DESIGNATION RESCINDED, BY STATUS, 2012-2016 (NUMBER)	22
FIGURE 6 FDA APPROVALS, BREAKTHROUGH DESIGNATION AND DESIGNATION RESCINDED, BY THERAPY AREA, 2012-2016 (NUMBER)	23
FIGURE 7 CARDIOVASCULAR BREAKTHROUGH THERAPY DESIGNATION DRUGS, BY STAGE (NUMBER)	24
FIGURE 8 CNS BREAKTHROUGH THERAPY DESIGNATION DRUGS, BY STAGE, 2016 (NUMBER)	33
FIGURE 9 INFECTIOUS DISEASE BREAKTHROUGH THERAPY DESIGNATION DRUGS, BY STAGE, 2016 (NUMBER)	52
FIGURE 10 CANCER DRUGS WITH BREAKTHROUGH THERAPY DESIGNATION, BY CANCER TYPE, 2016 (NUMBER OF APPROVED BTM DRUGS)	69
FIGURE 11 CANCER BREAKTHROUGH THERAPY DESIGNATION, BY COMPANY, 2016 (NO. OF BTM IN ONCOLOGY)	71
FIGURE 12 TREATMENT ALGORITHM FOR ALL PATIENTS	79
FIGURE 13 ENTINOSTAT MECHANISM OF ACTION	127
FIGURE 14 RARE DISEASE BREAKTHROUGH THERAPY DESIGNATION DRUGS, BY STAGE, 2016	158
FIGURE 15 OTHER DISEASES BREAKTHROUGH THERAPY DESIGNATION DRUGS, BY STAGE, 2016 (NUMBER)	173
FIGURE 16 COMPARISON OF APPROVAL TIMES STANDARD VERSUS BREAKTHROUGH DESIGNATION (MONTHS)	187
FIGURE 17 COMPARISON OF STANDARD AND BREAKTHROUGH THERAPY APPROVAL TIMES (MONTHS)	207